Ignite Creation Date:
2025-12-24 @ 2:30 PM
Ignite Modification Date:
2026-01-01 @ 12:40 PM
Study NCT ID:
NCT04377659
Status:
TERMINATED
Last Update Posted:
2025-05-28
First Post:
2020-05-04
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Study Overview
Official Title:
A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection
Status:
TERMINATED
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Based on two large, multicenter, randomized trials showed no benefit to tocilizumab in this setting and study has been closed.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: